Invivyd, Inc.

IVVD

Healthcare Biotechnology

Invivyd, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $53.4 million, up 110.5% from fiscal 2024.

Revenue
+21.2%
EPS
−16.7%
Free cash flow
−226.9%

Quarter to June 2026, against a year earlier

0.56 0.03 −5.08%
Market cap
$166.0M
P/E
n/m
Fwd P/E
n/m
Dividend yield
—
F-score
n/a
ROIC
−334.9%
Net debt / EBITDA
4.2×
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
3.74 7.96 7.21 4.78
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(22.69) (27.52) (9.65) (6.48)
P/B ratio
2.01 1.76 1.98 1.54
EV/Sales
2.04 3.72 3.91 2.03
EV/EBITDA
0.00 0.00 0.00 0.00
EV/FCF
(1.27) (3.41) (2.75) (1.08)
Current Ratio
2.47 7.24 6.47 5.87
Net Debt/EBITDA
8.02 18.70 4.32 3.54
Debt/Equity
0.00 0.00 0.00 0.00
Earnings Yield
(42.73%) (12.96%) (23.85%) (37.93%)
Free Cash Flow Yield
(42.97%) (13.70%) (19.74%) (39.34%)
Free Cash Flow per Share
(0.05) (0.09) (0.14) (0.14)
Book value per Share
0.55 1.40 0.66 0.57
Free Cash Flow
(8.25) (15.45) (42.44) (43.51)
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates